Thought Leadership

Latest Report


Q2 Roundup eBook

The first half of 2022 is behind us and for most in the industry, it was a six month period to forget. Have we hit the bottom, or will we plummet still further in the second half of the year?  This eBook digs into the business side of the biotech, pharma and medtech markets to look hard for any glimmers of hope to sustain us as we crack on…

Report library


Medtech - Going steady

The medtech sector, like the wider pharma market, has been having a tough time. There are, however, glimmers of light and some interesting developments – including…


Vantage Top 10 Most Read Report

The Evaluate Vantage team has rounded up our Top 10 Most-Read stories. Get up to speed on the big issues that have captured the interest and attention of your peers and…


Asco 2022 eBook

Thousands of abstracts were submitted for the recent Asco meeting in Chicago and 40,000 oncology professionals gathered to delve into cutting-edge research,…


Q1 2022: Choppy Waters eBook

If the first quarter of 2022 was a bellwether for the rest of year, many in the drug development market might want to don wet weather gear and hunker down for a blustery…


Orphan Drug 2022 Report

Treatments for orphan indications and rare diseases are no longer a niche area of focus for developers. Orphan products have become one of the fastest growing areas of…


Genetic Medicine: The Next Generation

Huge investment in the first generation of genetic medicine led, by and large, to incredibly high valuations for companies, and before too long, some in the market began…


Orphan Drug 2022 Infographic

In 2021, over half of the FDA’s new drug approvals were for orphan or rare diseases. While orphan products are one of the fastest-growing areas of drug development, it…